Halozyme Therapeutics (HALO) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 +0.64%
EPS Growth %: +17.5%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +17.5%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.4 million.
Halozyme Therapeutics sees FY2015 revenue of $85-95 million, versus the consensus of $93.3 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- MP Materials seen largely insulated after China export-control move
- Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
